Sandbox Reserved 1066: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 52: | Line 52: | ||
== Current Treatment == | == Current Treatment == | ||
The drugs developed thus far that have shown to inhibit mycolic acid biosynthesis are: isoniazid, ethionamide, isoxyl, thiolactomycin, and triclosan. <ref name="Drug Inhibitors"/> Additionally, pyrazinamide was shown to inhibit fatty acid synthase type I which is involved in providing a precursor necessary for fatty acid elongation to long-chain mycolic acids. <ref name="Drug Inhibitors"/> Treatment for active cases of tuberculosis include the simultaneous therapeutic use of two or more frontline drugs: isoniazid, ethambutol, rifampicin and pyrazinamide. <ref name="molecular studies"/> | |||
== Relevance of key mutational studies to the understanding and development of new inhibitors for FadD13 == | == Relevance of key mutational studies to the understanding and development of new inhibitors for FadD13 == | ||
